- Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap
- Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap
- Annovis Bio Files Patent for New Composition of Matter for Buntanetap
- Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson’s Disease Data
- Annovis Bio Highlights New Alzheimer’s Data at the Alzheimer’s Association International Conference® 2024
- Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients
- Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast
- Annovis Announces New Publication in a Peer-Reviewed Journal
- Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
- Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
More ▼
Key statistics
On Wednesday, Annovis Bio Inc (ANVS:NYQ) closed at 8.08, 78.37% above the 52 week low of 4.53 set on Jul 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.18 |
---|---|
High | 9.24 |
Low | 7.38 |
Bid | 7.81 |
Offer | 8.00 |
Previous close | 9.28 |
Average volume | 4.78m |
---|---|
Shares outstanding | 11.17m |
Free float | 8.36m |
P/E (TTM) | -- |
Market cap | 103.67m USD |
EPS (TTM) | -5.04 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 22:00 BST.
More ▼